Vaxcyte (PCVX) Other financing activities (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Other financing activities of $9.0 million for Q1 2026, up 49.31% year-over-year from $6.0 million in Q1 2025, and up 164.48% quarter-over-quarter from $3.4 million in Q4 2025.
Vaxcyte (PCVX) Other financing activities (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Other financing activities for 8 consecutive years, with $9.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 49.31% year-over-year to $9.0 million; the TTM figure through Mar 2026 stood at $16.0 million (down 43.24% YoY), while the FY2025 annual figure was $13.0 million, down 52.09% from the prior year.
- Other financing activities improved to $9.0 million in Q1 2026 per PCVX's latest filing, from $3.4 million in the prior quarter.
- Across five years, Other financing activities topped out at $11.7 million in Q3 2024 and bottomed at $268000.0 in Q2 2022.
- Historically, Other financing activities has averaged $3.9 million across 5 years, with a median of $3.8 million in 2023.
- Annual changes were most pronounced in 2024 — Other financing activities soared 900.8% — and 2025, when it plunged 97.39%.
- Vaxcyte's Other financing activities stood at $5.4 million in 2022, then slipped by 23.67% to $4.1 million in 2023, then surged by 45.77% to $6.0 million in 2024, then plunged by 42.93% to $3.4 million in 2025, then surged by 164.48% to $9.0 million in 2026.
- Business Quant data shows PCVX's Other financing activities at $9.0 million in Q1 2026, $3.4 million in Q4 2025, and $306000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.76 Mn |
| Jun 30, 2026 | 7.76 Mn |
| Mar 31, 2026 | 9.03 Mn |
| Mar 31, 2026 | 9.03 Mn |
| Dec 31, 2025 | 3.42 Mn |
| Dec 31, 2025 | 3.42 Mn |
| Sep 30, 2025 | 306,000.00 |
| Sep 30, 2025 | 306,000.00 |
| Jun 30, 2025 | 3.24 Mn |
| Jun 30, 2025 | 3.24 Mn |
| Mar 31, 2025 | 6.05 Mn |
| Mar 31, 2025 | 6.05 Mn |
| Dec 31, 2024 | 5.98 Mn |
| Dec 31, 2024 | 5.98 Mn |
| Sep 30, 2024 | 11.74 Mn |
| Sep 30, 2024 | 11.74 Mn |
| Jun 30, 2024 | 4.40 Mn |
| Jun 30, 2024 | 4.40 Mn |
| Mar 31, 2024 | 5.02 Mn |
| Mar 31, 2024 | 5.02 Mn |